icon on The FDA recently released a significant decision that will impact GLP-1 drugs, delisting semaglutide and tirzepatide from its shortage list - leading to heavy restrictions of compounded weight loss drugs often sold by online and telehealth pharmacies.
The decision is a big win for pharma companies Lilly and Novo.
Kevin Shortsle spoke to Amy Baxter of PharmaVoice about what this now means for the two companies, and how this might impact consumers.
Read the full article here: Lilly, Novo expand DTC reach of obesity meds after compound win | PharmaVoice.
Briefcase
Page Order
Page name
Reorder
Remove
Practices
Alternative Dispute Resolution Business and Corporate Corporate Transparency Act Business and Corporate Tax Tax Credits and Incentives Business Bankruptcy and Creditors' Rights Data Privacy and Cybersecurity Employee Benefits Environmental Franchising Intellectual Property Patent Trademark Copyright Intellectual Property Litigation Labor and Employment Litigation Business Litigation Intellectual Property Mergers and Acquisitions Real Estate Condominium and Homeowner Associations Securities Trust and Estate PlanningIntellectual Property I APRIL 7, 2025
Lilly, Novo expand DTC reach of obesity meds after compound win
Related Media
30
October
28
August
9
July
19
May
2
January
17
July
5
January
6
July
18
May
1
May
19
April
13
April
13
February
31
January
8
November
10
August
8
June
31
May
6
May
4
May
7
March
4
March
17
January
28
October
15
July
9
March
21
December
1
December
25
September
25
July
1
September
1
September
We're more than just business lawyers.
We're lawyers for your business.
From startup to maturity, we help businesses grow and succeed—assisting them with getting deals done,
resolving disputes, and complying with rules and regulations.